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Translational studyHuntington's disease (HD) is an autosomal dominant, progressive, and fatal neurodegenerative disorder
caused by an expanded polyglutamine cytosine–adenine–guanine repeat in the gene coding for the protein
huntingtin. Despite great progress, a direct causative pathway from the HD gene mutation to neuronal
dysfunction and death has not yet been established. One important advance in understanding the pathogenic
mechanisms of this disease has been the development of multiple murine models that replicate many of the
clinical, neuropathological, and molecular events in HD patients. These models have played an important role
in providing accurate and experimentally accessible systems to study multiple aspects of disease
pathogenesis and to test potential therapeutic treatment strategies. Understanding how disease processes
interrelate has become important in identifying a pharmacotherapy in HD and in the design of clinical trials.
A review of the current state of HD mouse models and their successes in elucidating disease pathogenesis are
discussed. There is no clinically proven treatment for HD that can halt or ameliorate the inexorable disease
progression. As such, a guide to assessing studies in mouse models and salient issues related to translation
from mice to humans are included.Published by Elsevier B.V.1. Introduction
Huntington's disease (HD) is an autosomal dominant inherited
neurodegenerative disorder that is characterized by progressive
motor dysfunction, emotional disturbances, dementia, and weight
loss. Although the disorder had previously been reported, the initial
detailed description of HD was that of George Huntington, a medical
practitioner of Pomeroy, Ohio, in 1872 [1]. He gave a detailed account
of the disease based upon the descriptions taken by his father and
grandfather from their practice in East Hampton, Long Island, NY.
Those patients could be traced to a few individuals that had emigrated
from a small village in Suffolk, England in 1630. Neuropathologists had
previously described HD as a chronic encephalitis [2]. In 1908,
however, Jergelsma ﬁrst described the characteristic neuropathologic
alterations within the basal ganglia [3]. HD occurs worldwide, in all
races and ethnic groups [4]. Its prevalence is 5–10 cases per 100,000,
and there is a new mutation rate as high as 1–3% [5]. There are about
30,000 affected individuals in the United States. Another 150,000
Americans have a genetic risk for developing the disease. The average
age of onset is 38 years of age, however the range is from infancy into
the ninth decade. There is increasing reason to believe that pathologic
alterations occur in the brain years before symptomsmanifest [6–8]. A
recent MRI study of gray matter in presymptomatic HD patients closeB.V.to estimated diagnostic onset, using a weighted VBM voxel procedure,
showed degenerative changes in the striatum, in contrast to control
subjects [8]. Once symptomatic, affected individuals are rapidly
disabled by early functional decline, and require increasing care and
supervision for another 15–25 years before succumbing to the effects
of severe physical and mental deterioration. In approximately 25% of
patients with HD, the ﬁrst symptoms appear after age 50 [9]. The rare
juvenile form of HD, which is associated with the rigid-type or
Westphal variant, is found in 2% of the total population having the
disease [10]. Because of early functional decline, the chronic and the
increasingly intensive multidisciplinary care it requires, and its
genetic nature, HD disproportionately consumes medical, social, and
family resources [11].
The HD gene, ﬁrst cloned in 1993 [12], codes for a large, highly
conserved protein (huntingtin) of unknown function that is found in
neurons throughout the brain. Emerging evidence, however, suggests it
is involved in fast axonal transport [13,14], speciﬁcally enhancing
vesicular transport of brain-derived neurotrophic factor along micro-
tubules [15]. Rather than a simplemissensemutationordeletion, theHD
gene defect is an expanded unstable DNA segment, containing a
polymorphic trinucleotide cytosine–adenine–guanine (CAG) repeat in
the coding sequence of the IT15 gene on chromosome 4. In individuals
with HD, a polymorphic trinucleotide repeat sequence (CAGn), near the
5′ end of the gene, is expanded beyond the normal repeat range, leading
to the translationof anexpandedpolyglutamine sequence in theprotein.
In the normal population, the number of CAG repeats varies from 17
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expanded into the pathogenic ranges, there is an inverse relationship
between the CAG repeat number and the age of onset, with higher
repeat associated with younger age and greater severity. In HD, both
normal andmutant alleles are expressed. Gain-of-function alterations in
which mutant huntingtin has protein-level toxicity, as well as loss of
function of normal huntingtin, have been proposed to contribute to HD.
Expansion of trinucleotide repeats is now well recognized as a
major cause of neurological disease [16–18]. HD is one member of the
family of neurodegenerative triplet repeat disorders with anticipation
and a gain- or change-of-function mutation. These include spinocer-
ebellar ataxias, dentato-rubro-pallido-luysion atrophy, Machado–
Joseph disease, and spinal bulbarmuscular atrophy. As in HD, selective
loss of neurons underlies these diseases and misfolding and abnormal
aggregation of the mutant protein occur. It has thus been hypothe-
sized that neurodegeneration in these disorders may have similar
molecular bases. Interestingly, the pathogenic mechanisms in HD are
also themes relevant for other neurodegenerative disorders, including
Parkinson's, amyotrophic lateral sclerosis, and Alzheimer's diseases.
Despite great progress, a direct causative pathway from the HD
gene mutation to neuronal dysfunction and death has not yet been
established. Although the exact cause of neuronal death in HD
remains unknown, it has been postulated that proteolysis of mutant
huntingtin plays a role in disease pathogenesis, resulting in an
abnormal and toxic amino acid (N)-terminal fragment that forms
protein aggregates in neurons. While these aggregates induce
chaperone expression and become ubiquitinated, they persist,
indicating protein misfolding [19] and failed proteosomal function
[20]. They also sequester a variety of other important cellular proteins
including chaperones [21], proteasomal proteins [22], normal hun-
tingtin [19], and transcription factors [23], as another means of
disturbing protein homeostasis [24]. These aggregates can be readily
detected throughout the course of the disease [25–27]. While no one
speciﬁc protein–protein interaction of mutant huntingtin has been
suggested to be the pathologic trigger, evidence has accumulated that
direct interactions between mutant huntingtin and transcription
factors may be the proximal defect that underlies transcriptional
dysfunction [23]. This then results in a cascade of compensatory and
damaging events to molecular processes and genetic programs that
ultimately lead to neuronal death. These pathological events include
oxidative stress, mitochondrial dysfunction, altered receptor activities,
inﬂammation, pro-apoptotic signals, bioenergetic defects, increased
transglutaminase activity, and excitotoxicity [28].
Basal ganglia pathology has been themost thoroughly characterized
and has been central to the development of animal models and
hypotheses about the circuitry involved in chorea and about potential
mechanisms of neuronal death in HD.While cerebral cortical changes in
HD occur early and are topographically selective to subcortical white
matter in premanifest disease [29,30], the most striking early neuro-
pathological feature is marked gross atrophy of the neostriatum with
concomitant neuronal degeneration within the caudate nucleus and
putamen [31,8]. There is a topographic progression of neuronal loss and
astrogliosisﬁrst observed in thedorso-medial aspect of the striatumand
progressing ventro-laterally, with relative sparing of the ventral
striatum [32]. The striosomal/matrix pattern in the neostriatum is
topographically altered in HD, with the total area of matrix reduced and
the areaof the striosomesunchanged. Theseﬁndings are consistentwith
the preferential loss of striatal D1 receptors. Not all neurons, however,
are affected equally within the neostriatum [33]. The hallmark of
neuropathology in HD is selective neurodegeneration in which vulner-
able populations of neurons degenerate, while less vulnerable popula-
tions are spared [33]. While large cholinergic neurons and medium-
sized nicotinamide adenine dinucleotide phosphate (NADPH)-diaphor-
ase aspiny neurons remain relatively spared in HD, medium-sized spiny
γ-aminobutyric acid (GABA)-ergic projection neurons of the striatum,
which make up roughly 90% of striatal neuron content, are dispropor-tionately affected early and most severely [34–36]. There is also a
reduction in striatal neurochemicals that parallels striatal neurodegen-
eration in HD [37], with enkephalin-expressing striatal projection
neurons appearing more vulnerable in early adult-onset HD, in
comparison to substance P striatal neurons [38]. It is of interest to
note that substance P is found in both spiny and aspiny neurons in a
70:30% ratio respectively [39]. Some substance P neurons, however, are
still present throughout HD striatum. The majority of these preserved
neurons have been characterized as aspiny, using light and electron
microscopic methods [40]. In addition, striatal medium spiny neurons
show both proliferative and degenerative changes in the prolonged
process leading to neuronal dysfunction and cell death [41,42].
The pathogenic signiﬁcance of cytosolic and nuclear mutant
huntingtin aggregation remains unclear. Ongoing debate continues,
as with other neurodegenerative disorders in which protein aggre-
gates are a hallmark of disease, questioning whether inclusions,
otherwise referred to as intracellular agglomerates, formed by the
aggregated N-terminal truncation of huntingtin cause neuronal death
through alterations of nuclear transport or DNA arrangements
affecting transcription [23]. Nuclear inclusions are largely made up
of cleaved N-terminal products, whereas cytoplasmic inclusions
contain both cleaved and larger intact proteins [43]. In general,
huntingtin aggregates are ubiquitous and in large numbers through-
out HD mouse brain models [44], while largely conﬁned to the
neocortex with little or no aggregates observed in the neostriatum of
HD patients [25,27]. It is unlikely that the latter can be explained by
unrecognized aggregates or their rapid formation and loss. Nuclear
huntingtin and ubiquitin aggregation is present well before the
neurological deﬁcits occur in transgene animal models, implicating
nuclear aggregation in neuronal dysfunction and subsequent death in
HD [45,46]. Interestingly, ‘shortstop’ YAC transgenic mice have
widespread nuclear huntingtin inclusions, yet demonstrate no
signiﬁcant HD phenotype [47] and suggest that not all mutant
huntingtin fragments are toxic [48]. As such, rather than a harbinger
of neuronal death, mutant huntingtin aggregation may be a
cytoprotective mechanism inactivating polyglutamine-induced neu-
rotoxicity by sequestering the mutant protein until ubiquitination can
dismantle it. As such, huntingtin inclusions may not be a key player in
the pathogenic events leading to selective neuronal death nor a
predictor of neuronal death [27,49–51]. It may well be that soluble
mutant huntingtin fragments engage pathologic interactions and that
neuronal death may be dependent upon the levels of diffuse
unaggregated huntingtin found in affected neurons and provide an
explanation for the pattern of striatal neuron loss [52,53]. It is difﬁcult,
however, to reason that such factors as the mass effect of cytosolic and
nuclear huntingtin aggregate burden, the sequestration of essential
cellular transcription factors and neuronal proteins and their
subsequent reduced activity [54], altered proteosomal function [55],
and the localization of mutant huntingtin aggregates to cellular
organelles such as mitochondria [56], do not have a deleterious effect
upon neuronal function and survival. In defense of this comment,
select therapies reduce huntingtin aggregates in HD mouse models
and are thought to be responsible, at least in part, for the signiﬁcant
improvement of the behavioral and neuropathological phenotype
found in these mice [28,57]. In addition, the blockade of mutant
huntingtin in a conditional murine model of HD reduces inclusions
and ameliorates the behavioral phenotype [58].
While great strides have been made in understanding the
pathogenesis of HD, there is still an incomplete understanding of
the disease mechanisms. Animal toxin and genetic models that closely
mimic the neurobiological and clinical symptoms of the disease may
provide an alternative approach for the study of HD molecular
pathogenesis and in the development of existing treatments and novel
therapeutic strategies for HD. Therefore, animal models are a crucial
part of this rapidly advancing ﬁeld of HD research. In this chapter,
animal models are reviewed in association with implications in
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therapies is discussed along with a guide to assessing preclinical trials
in mouse models.
2. Toxin models of HD
2.1. Excitotoxin lesions in animals
A suitable animal model of HD must at least replicate the
neuropathological features of the disorder as described above. An
increasing body of evidence suggests that excitotoxicity plays a role in
both acute and chronic neurological diseases. One of the earliest
experimental models of HD was established in rats and mice and
included the direct introduction of excitatory agonists into the central
nervous system. Lucas and Newhouse ﬁrst observed retinal degenera-
tion in mice after systemic administration of glutamate [59]. This was
followed by the demonstration that excitatory amino acids mediated
cell death in anoxic hippocampal cultures [60]. The initial observation
suggesting that excitotoxicity may play a role in HD was made by the
McGeers and Coyle and Schwarcz [61,62]. Both groups of investigators
showed that injections of the excitatory glutamate-type neurotoxin,
kainic acid, produced degeneration of striatal GABAergic projection
neurons with preservation of striatal afferents, resembling the
neuropathological sequelae observed in HD. This model was reﬁned
by using N-methyl-D-aspartate (NMDA) type excitotoxins, including
quinolinic acid, an endogenous intermediate in the kynurenine
pathway of tryptophan metabolism. Quinolinic acid is elevated in
HD patients, the increased levels possibly derived from activated
microglia, resulting in neurodegeneration [63]. Unlike kainic acid,
quinolinic acid shows differential sparing of striatal neurons.
Quinolinic acid damaged both GABAergic and substance P-containing
neurons, with relative sparing of NADPH-diaphorase and cholinergic
neurons, that latter of which are known to be spared in HD [34,35]. Of
interest to note, quinolinic acid administration results in an age-
dependent decrease in enkephalin neuron vulnerability in contrast to
substance P striatal neurons [64]. Others and we have demonstrated
that intrastriatal injection of quinolinic acid produced a more accurate
model of HD [65,66]. Other NMDA agonists also reproduce relative
sparing of NADPH-diaphorase neurons [67]. Chronic quinolinic acid
lesions, where months have passed to allow resorption of the necrotic
injection site, closely reproduce the patterns of selective neuronal
sparing in the rat striatum and cerebral cortex found in HD [68].
Excitotoxin lesions in the monkey, using quinolinic acid, provide an
experimental primate model that closely resembles the neuropatho-
logical, neurochemical, and clinical features of HD [66]. These lesions
were characterized by a central zone of intense astrogliosis and
marked neuronal depletion. Immunocytochemical and enzyme
histochemical markers for both large and medium-sized aspiny
striatal neurons and spiny striatal neurons clearly demonstrated a
selective pattern of neuronal vulnerability and relative resistance to
the excitotoxic effects of quinolinic acid within lesioned striata. There
was a disproportionate involvement of the matrix compartment
similar to that seen in HD. These changes were accompanied by
behavioral alterations suggestive of a hyperkinetic movement dis-
order. Dopaminergic agonist-inducible chorea was observed in the
primates and was indistinguishable from that seen in HD [69].
Ultrastructural analysis conﬁrmed axon-sparing lesions with neuronal
loss and astrogliosis. Nonphosphorylated neuroﬁlament immunor-
eactivity was reduced in cell bodies but increased in axons, consistent
with NMDA-mediated activation of the calcium-dependent phospha-
tase, calcineurin, which dephosphorylates neuroﬁlament protein [70].
These animal models demonstrate a characteristic proﬁle consistent
with the features of HD and strongly suggest that an excitotoxic
process plays a role in the pathogenesis of this disorder. If an NMDA
excitotoxic process plays a role in the selective neuronal degeneration
in HD, neurons containing high densities of these receptors should bepreferentially vulnerable, resulting in a depletion of these receptors.
This is indeed the case. Young et al. have shown that NMDA receptors
are differentially depleted as compared to other receptor subtypes
[71].
It is well established that striatal excitotoxic lesions depend on
corticostriatal glutamatergic inputs [72,73]. There is also a substantial
body of evidence indicating that striatal excitotoxic lesions are
dependent on dopaminergic inputs from the substantia nigra
[72–74]. Nigrostriatal dopaminergic neurotransmission is altered in
HD based on early and dramatic changes in related receptors and may
contribute to striatal vulnerability in HD. More directly, released
dopamine can be a stressor to striatal neurons through oxidative
mechanisms, as well as modulation of glutamate release [75–77]. It is
possible that both cortical and nigral afferent inputs may be
responsible for the regional selectivity of neuronal degeneration that
is observed in HD.
2.2. Defective energy metabolism toxin models
While an abnormality affecting the NMDA receptor or an increased
endogenous excitotoxin could be responsible for HD, candidate toxins,
such as quinolinic acid, however, are not increased in this disease. A
novel hypothesis explaining the pattern of degeneration in HD has
evolved based on animal studies and observations in HD patients. It
suggests that impaired cellular energy may be involved in the
degenerative process [78,79]. The initial relevant observations were
made by Olney who showed that partial membrane depolarization
can produce NMDA receptor-mediated excitotoxicity by removing the
voltage-dependent magnesium block of the NMDA-linked calcium
channel [80–81]. The open calcium channel permits normal amounts
of endogenous glutamate to produce NMDA receptor-mediated
neurotoxicity. Evidence suggests that energy depletion producing
partial membrane depolarization also produces NMDA-type excito-
toxic lesions [81–82].
It is of great interest that energy failure may be the consequence
of impaired electron transport chain function, with subsequent
reduced ATP stores that result in membrane depolarization, removal
of magnesium from the NMDA-linked calcium channel, and
subsequent excitotoxic injury. The electron transport chain is
comprised of a series of enzymes, consisting of ﬁve major complexes.
It is one of a series of reactions that are involved in oxidative
phosphorylation. A proton gradient generated by the electron
transport chain complexes I, II, and III, stores potential energy for
the synthesis of ATP along with reducing oxygen to water. Impaired
electron transport chain function produces energy failure that results
in membrane depolarization, removal of magnesium from the
NMDA-linked calcium channel, and subsequent excitotoxic injury.
Several electron transport chain enzymes have been shown to be
altered in HD. Cytochrome oxidase (Complex IV) abnormalities have
been reported in HD caudate nucleus [83]. The loss of cytochrome
oxidase in damaged brain areas, however, may be a consequence of
neuronal loss rather than a cause. Studies of platelets from HD
patients suggest that Complex I activity may also be selectively
decreased in HD patients, although it is normal in at-risk family
members [84]. Other electron transport chain complexes, including
Complex II (succinate ubiquinol oxidoreductase), Complex III
(ubiquinol cytochrome c reductase) and Complex IV (cytochrome
oxidase) are normal in blood platelets [84]. Decreased activity of
Complex II/III of the electron transport chain has been found in the
caudate nucleus, but not in other brain areas in HD [85]. Beal et al.
have demonstrated a 22% decrease in Complex II–III activity in the
caudate nucleus and a signiﬁcant increase in Complex I activity in
the frontal cortex, which may be compensatory [86]. It is possible
that the mutation in HD affects a nuclear encoded component of
Complex II, Complex I, or the process of protein translocation and
import into mitochondria.
509R.J. Ferrante / Biochimica et Biophysica Acta 1792 (2009) 506–520Over 30 years ago,Mettler showed that sodium azide, a Complex IV
(cytochrome oxidase) inhibitor, produced striatal damage and a
hyperkinetic movement disorder in primates [87]. More recent animal
studies show that striatal injections of mitochondrial toxins produce
differential neuronal toxicity identical to that produced by NMDA
receptor agonists [88–91]. Several speciﬁc inhibitors, such asmalonate
and 3-nitropropionic acid (3-NP), act at various complexes of the
electron transport chain. A naturally occurring plant toxin and
mycotoxin, 3-NP, has been associated with neurological illness in
animals and humans [92]. 3-NP is an irreversible inhibitor of succinate
dehydrogenase that inhibits both the Krebs cycle and Complex II
activity of the electron transport chain. Ingestion in cattle causes
dyspnea, hindlimb weakness, and motor abnormalities [92,93]. In
China, accidental human systemic ingestion of 3-NP from contami-
nated sugar cane has resulted in neurologic sequelae that include
encephalopathy with stupor and subsequent coma. A delayed-onset
nonprogressive dystonia with jerk-like movements and facial grima-
cing results in those patients that recover. Brain imaging has identiﬁed
bilateral damage to the basal ganglia, particularly the putamen.
In vitro studies have shown that 3-NP reduces cellular levels of ATP
and causes neuronal damage by an excitotoxic mechanism [94]. We
have demonstrated that systemic administration of 3-NP to both rats
and primates can produce selective striatal lesions that are a
consequence of secondary excitotoxic mechanisms [95–96]. These
lesions accurately replicate a number of motor and neuropathological
symptoms observed in HD patients. Systemic administration results in
differential sparing of striatal NADPH-diaphorase and large choliner-
gic neurons with a signiﬁcant loss of striatal GABAergic neurons. Both
enkephalin and substance P striatal neurons, however, are equally
affected by 3NP, a ﬁnding that is inconsistent with those present in
adult-onset HD [97]. 3-NP is the ﬁrst neurotoxin to show an age-
dependent neurotoxicity. The age-dependent neurotoxicity of 3-NP
observed in young adult rats in these studies is similar to the typical
age of onset in HD. Both freeze-clamp measurements and chemical
shift magnetic resonance spectroscopy show that 3-NP impairs energy
metabolism in the striatum in vivo. While intrastriatal injection of 3-
NP results in striatal neuronal death in rats, neurochemical and
histologic evaluation shows that markers of both spiny projection
neurons (GABA, substance P, calbindin) and aspiny interneurons
(somatostatin, neuropeptide Y, NADPH-diaphorase) are equally
affected in intrastriatal injections [95].
Interestingly, the lesions produced by intrastriatal injection or
systemic administration of 3-NP are blocked by prior decortication,
suggesting that intact corticostriatal glutamatergic innervation plays
an important role in striatal degeneration produced by systemic
administration of 3-NP. As glutamate is a central tenant in provoking
excitotoxic cell death in striatal neurons already weakened by the
collective molecular events occurring in HD, it is of interest to note
that the modulation of other neurotransmitters, such as dopamine,
can contribute to the neurodegeneration in HD. In addition, the
modulation of A2a receptors can ameliorate 3-NP-induced neuronal
damage [98]. In primates, chronic 3-NP administration produces
selective bilateral striatal lesions characterized by a depletion of
calbindin neurons with sparing of NADPH-diaphorase neurons, and
proliferative changes in the dendrites of spiny neurons.
Lesion approaches in experimental animals using selective
neurotoxins have made it possible to clarify the mechanisms that
underlie the hyperkinesis [99–101]. It has been suggested that there is
a shift in the pathways of the basal ganglia/thalamocortical circuit in
HD [101]. Animals also show both spontaneous and apomorphine-
inducible choreiform movement disorders resembling those in HD.
These ﬁndings clearly associate metabolic stress and striatal neuron
vulnerability. It is of interest to note that differences in the periodicity
of excitotoxin injections and total dosing levels result in the reported
differences in susceptibility. Acute treatments consisting of a single i.p.
dose of 3-NP rapidly lead to striatal degeneration within 6–12 h afterinjection [102–104]. Subacute treatments consisting of daily repeated
intraperitoneal injections lead to striatal degeneration over a few days
[95,105,106]. Chronic treatments are based on continuous systemic
administration of 3-NP (over 5 days to 4 weeks depending on the
protocol) using osmotic minipumps implanted subcutaneously. Of
great interest is the fact that toxicity in rodents is dependent upon the
strain and gender of experimental animal used [107].
Unfortunately, systemic administration of 3-NP is not speciﬁc to
the CNS alone. There is now very strong data to suggest that 3-NP has
severe cardiotoxic effects in addition to neurotoxicity [108]. It may be
unclear what the underlying cause of the mortality and clinical
phenomena observed in 3-NP toxicity are and to what degree
peripheral damage contributes to the clinical and neuropathological
outcome measures. As such, postmortem analysis of somatic organs,
especially the heart, in assessing pathological involvement is critical in
determining the involvement of systemic and neurological contribu-
tions to CNS damage. While 3-NP toxicity replicates a number of the
cell death mechanisms associated with HD (e.g. electron transport
activity inhibition and mitochondrial dysfunction, activation of the
apoptotic cascade and execution proteases, increased reactive oxygen
species production, and proteolytic calpain activation), transgene and
full-length mutant huntingtin rodent models provide the best
possible molecular and genetic comparability and pathophysiological
correlation to humans with HD. Although toxin models do not help to
advance our understanding of the pathogenicity of expanded
polyglutamine tracts, this is not to suggest that the 3-NP model is
not without merit. The 3-NP model continues to enrich our under-
standing of speciﬁc pathophysiological phenomena in HD associated
with excitotoxicity and mitochondrial dysfunction.
3. Genetic models of HD
Genetic models have revolutionized the study of human neurolo-
gical diseases by providing accurate and experimentally accessible
systems in which to study molecular pathogenesis. Genetic models
also provide an opportunity to test potential treatments and explore
their promise for translation to humans experiencing these diseases.
The promise of using genetic models for treatment discovery is
perhaps greatest in inherited diseases, such as HD, which affect single
genes. It must be said, however, that even the genetic models of HD
are not perfect, since there are subtle differences in the huntingtin
gene from the human orthologue along with dissimilar promoters. In
addition, the polyglutamine repeats in some genetic models are quite
long and have been suggested to replicate themore fulminant juvenile
form of HD and not necessarily the adult-onset form of the disease.
The degree of over-expression of mutant protein plays a signiﬁcant
role in the phenotype observed in mice. The gold standard is the
human condition and no genetic model replicates all of the ﬁndings in
HD patients. Each model, however, has valid and useful experimental
outcomes that can be used to provide a greater understanding of the
disease process in humans and especially in identifying potential
therapeutic strategies. While mutant huntingtin has been expressed
in a number of invertebrate and vertebrate species in modeling
different aspects of the HD phenotype, this review will concentrate on
mouse models, since they are the most common experimental tool
currently in use.
Different genetic mouse lines have been generated with varying
phenotypes as a product of how the mutant huntingtin was
incorporated into the mouse genome. They fall into three broad
categories: (1) mice that express exon-1 or exon-1 and 2 of the human
huntingtin (htt) gene containing polyglutaminemutations (in addition
to both alleles of murine wild-type huntingtin, Hdh) [109–111]; (2)
mice with pathogenic CAG repeats inserted into the existing CAG
expansion in murine Hdh (knock-in mice) [112–118]; and (3) mice
that express the full-length human HD gene (plus murine Hdh)
[119,120]. Although all of thesemodels share features with human HD,
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gradually over many months and may not have a sufﬁcient expression
of disease to use progressive morbidity and survival as endpoints.
Although the full-length models are genetically more accurate, the
fragment models have a rapidly coursing robust phenotype, well-
deﬁned neurobehavioral and neuropathological ﬁndings, and die
between 3 and 4 months of age. It has been a common practice to use
the fragment models for therapeutics research because the outcomes
are more clearly established and trials are more easily conducted
[121]. The ideal transgenic mouse model should have a robust
phenotype, moderate to rapid disease onset and progression, well-
deﬁned behavioral abnormalities that can be quantiﬁed, and neuro-
pathological features, all of which accurately replicate human HD.
3.1. Fragment/segment genetic murine models of human HD
Not surprisingly, the degree of similarity to human HD increases
the closer the model reproduces the exact neuropathological and
molecular conditions for HD. Unfortunately, the more genetically
accurate the model is, the more subtle the phenotype. Thus, it has so
far been much more feasible to use the fragment models for
therapeutics research because the outcomes are more prevalent and
deﬁnable; hence, trials can be conducted using smaller sample sizes.
This category of genetic mice expresses N-terminal fragments of
human HD and includes the R6/2, R6/1 and N171-82Q lines (Table 1).
They show a relatively rapid onset and progression of a phenotype
that includes weight loss, motor performance abnormalities, neuro-
pathological sequelae, and a shortened lifespan.
3.1.1. R6/2 transgenic mice
The R6/2 line was the ﬁrst transgenic mouse model of HD and has
an N-terminal fragment of htt (exon 1) with approximately 144–150
CAG repeats at exon 1 [109]. It is one of the most widely employed
genetic models of HD. The R6/2 model exhibits a progressive
homogeneous HD-like phenotype, with survival ranging from 14 to
21 weeks, depending on housing and facility conditions. Differences in
survival duration may be the result of variations in housing, handling,
environmental enrichment, and the allowable presence of viral and
bacterial symbionts, in addition to other factors. Given that enriched
environments can alter the progression of behavioral phenotype in
R6/2 mice [122], it stands to reason that differences between
laboratories may well alter the R6/2 phenotype. This mandates that
within any colony of R6/2mice, a repeatablemeasurement of survival,
or any other phenotypic measurement, is paramount for each
successive “f” generation.
Recent ﬁndings suggest that the R6/2 HD model exhibits a
progressive HD-like behavioral and neuropathological phenotypeTable 1
N-terminal fragment models of human HD.
Rodent model CAG repeat Behavioral changes Neur
R6/1 mouse 116 Signiﬁcant body weight loss at 22 weeks.
Motor performance abnormalities at 4–5 months.
Redu
but n
are p
R6/2 mouse 144–150 Dystonia with limb clasping by 6 weeks. Body
weight loss by 8–9 weeks. Reduced hindlimb and
forelimb performance by 9 and 11 weeks,
respectively. Rotarod changes by 5 weeks.
Seizures. Diabetes
Signi
atrop
Prog
by 90
start
dopa
N171-82Q mouse 82 Body weight loss Motor performance deﬁcits,
and limb clasping by 11 weeks.
Water maze deﬁcits at 14 weeks.
Gros
striat
aggre
Transgenic rat 51 Progressive rotarod decline by 2 months, with
signiﬁcant body weight loss by 24 months.
Cognitive deﬁcits by
12 months. Head dyskinesias by 10 months.
Hype
incluthat more closely corresponds to human HD than previously believed,
providing further assurance that the R6/2 mouse is an appropriate
model for testing potential therapies for HD [44]. Behavioral analyses
of the R6/2 mouse reveal age-related impairments in dystonic
movements, motor performance, grip strength, and body weight
that progressively worsen until death. There is a very small subset of
R6/2 mice, less than 2%, that die prematurely through constant
seizure activity (status epilepticus). Thismay occur as early as 60 days.
Over-handling of these mice may exacerbate seizure activity.
Signiﬁcant neuropathological sequelae, identiﬁed as increasing
marked reductions in brainweight, are present from 30 days, whereas
decreased brain volume and hyperventricular enlargement is present
from 60 days, both a hallmark of the disease. In addition, decreased
neostriatal volume, striatal neuron atrophy, increased astrogliosis,
with a concomitant reduction in striatal neuron number, are present
at 90 days of age [44]. Consistent with early adult-onset HD,
enkephalin striatal neurons are reduced in comparison to substance
P striatal projection neurons [97]. There is, however, equal preserva-
tion of enkephalin and substance P striatonigral projections.
Huntingtin-positive aggregates are present at postnatal day 1 and
increase in number and size with age, suggesting that disease onset
and progression occur before clinical phenomena [44]. The huntingtin
inclusions are extensive and found throughout the brain in great
numbers, a phenomenon that is inconsistent with that observed in HD
patients. It has been suggested that the latter may be the result of
using only a portion of the HD gene, transgene effects, and the use of
foreign promoters that increase expression levels. There does not
appear to be any gender differences in the pathological phenotype.
There is remarkable parallelism between the reported mechanisms of
disease pathogenesis observed in HD patients and those found in the
R6/2 mice, which include altered proteolysis and proteosomal
activities, increased protein crosslinking, induced chaperone expres-
sion, and defects in vital cellular processes that comprise endocytosis,
intraneuronal trafﬁcking, transcriptional regulation, postsynaptic
signaling, apoptotic cascades, and alterations in bioenergetic meta-
bolism and mitochondrial function [28,57,123].
Although the R6/2model hasmany of the temporal behavioral and
neuropathological features observed in HD patients, it is not an exact
genetic and neuropathological correlate to HD patients. While some
disparity exists in the speciﬁc aspects associated with onset and
presence of both neuropathological and behavioral alterations
observed in the R6/2 mice, with resulting potential confound
[124–127], these differences may just be the result from varying
methodological practices. Nevertheless, the R6/2 model has a well-
characterized progressive phenotype with moderate variability such
that experimental groups can contain as few as 10 mice and provide
the power to detect 10% differences in many outcome measures. It isopathology Survival References
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ot neuronal loss is present. Huntingtin aggregates
resent at 2 months. Reduced dopamine levels.
12+ months [97,119]
ﬁcant brain weight loss at 30 days. Gross brain
hy by 60 days with hyperventricular enlargement.
ressive neuronal atrophy with neuronal loss
days. Progressive huntingtin aggregate formation
ing at day 1. Astrogliosis at 90 days. Reduced
mine levels.
12–18 weeks [97,111]
s brain atrophy, hyperventricular enlargement,
al neuron atrophy and loss, and huntingtin
gate presence by 16 weeks.
130–180 days [98,126,127,128]
rventricular enlargement and huntingtin
sions. Striatal neuron loss.
None reported [134,135]
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indicator for neuroprotection, in approximately 3 months. R6/2 mice
have been used in a number of preclinical therapeutic trials [28,57]
that have recently been translated to human clinical trials [28,57,123].
The efﬁciency and clear experimental endpoints of the R6/2 mice
remain a major advantage.
It has been long held that synaptic stress may contribute to the
neurodegeneration in HD and, as such, modulation of synaptic
inﬂuences in R6/2 mice, that is glutamatergic and dopaminergic
transmission, ameliorates disease progression. Deafferentation of the
corticostriatal and nigrostriatal pathways mitigates striatal stress
and neurodegeneration. Both surgical and chemical lesions of the
corticostriatal and nigrostriatal pathways, respectively, improve the
behavioral, neuropathological, and biochemical phenotype in R6/2
transgenic mice and extend survival [128]. Decortication ameliorates
hindlimb clasping, striatal neuron atrophy, and huntingtin-positive
aggregates, improves N-acetyl aspartate/creatine levels, reduces
oxidative stress, and signiﬁcantly lowers striatal glutamate levels.
In addition, 6-hydroxydopamine-lesioned R6/2 mice show extended
survival along with a signiﬁcant reduction in striatal glutamate.
There can be great variability in phenotype presentation, which is
dependent on CAG repeat size. The number of CAG repeats in the
R6/2 line is 148–153 with 500–550 bp, as determined by PCR
analysis [44]. An increased number of base pairs greater than 550
results in moderation of the severity of the R6/2 phenotype. With
increasing base pair numbers, there is a concomitant increase in CAG
repeat size. R6/2 mice in which the base pairs ranged between 600
and 800 have CAG repeat sizes between 175 and 192. The average
survival extension signiﬁcantly increased in age to 131.4±12.1 days,
in contrast to 500–550 bp at 97.4±0.58 days. Base pair numbers of
1000 and above have CAG repeat sizes consistently above 200, with a
mean survival of 147.9±15.6 days. We have found that the
variability in survival and the amelioration of the behavioral and
neuropathological phenotype in R6/2 mice with increased base pair
number and CAG repeat size reduces their utility in therapeutic trials
and may confound results [44]. Although great variability in clinical
measures is common in human trials, minimizing measurement
variability increases the power to detect differences in mouse drug
trials. Thus care should be taken to ensure that genetic variability is
reduced, providing a relatively homogeneous population of mice
within experimental cohorts.
3.1.2. R6/1 transgenic mice
The R6/1 mice were developed at the same time as the R6/2 mice
and express exon 1 of the human HD gene with approximately 116
CAG repeats. The R6/1 mice have not been as well studied as the R6/2
mice [109]. The R6/1 line has a later age of onset and a slower disease
progression. Body weight loss occurs after 22 weeks [129]. They
exhibit motor performance abnormalities, as limb clasping, at 4–
5 months. There is a signiﬁcant decline in rotarod performance
between 14 and 20 weeks that correlates with the presence of
huntingtin aggregates in striatal neurons. There are gait abnormalities
and hindlimb clasping similar to the R6/2 mice. These mice can live
beyond 12 months. Brain volume is signiﬁcantly reduced by 18 weeks
with striatal neuron atrophy. There is, however, no neuronal loss, as
identiﬁed by neuron-speciﬁc nuclear protein NeuN ormet-enkephalin
immunostaining in the striatum [129]. Huntingtin aggregates do not
appear until 2 months of age. Although it has been reported that both
R6/1 and R6/2 mice are resistant to excitotoxic lesions produced by
quinolinic acid and malonate [130,131], it is possible that the latter
may be attributable to a marked reduction in dopamine levels in the
R6/1 mice and R6/2 mice [132,133]. In the R6/1 mice, extracellular
dopamine levels are reduced by 70% compared with wild-type
littermates, and intrastriatal administration of malonate in these
mice resulted in signiﬁcantly smaller lesion size [134]. In contrast, we
have showed that R6/2 mice are more susceptible to the mitochon-drial toxin, 3-nitropropionic acid [135]. It may well be that differences
in the periodicity of excitotoxin injections and in total dosing levels
result in the reported differences in susceptibility. Equally, back-
ground strain may play a role in resistance [136]. Of interest to note,
reduced sensitivity to excitotoxins may be dependent upon age and
CAG repeat length [137].
3.1.3. N171-82Q transgenic HD mice
N171-82Q mice have an N-terminal fragment of huntingtin
incorporating both exon 1 and exon 2 of the huntingtin gene, with
82 polyglutamines [110]. The N-terminal fragment is driven by the
mouse prion promoter and expression is restricted to neurons and no
other cells in the CNS. The mice contain two wild-type copies of the
gene along with onemutant copy. The phenotype of N171-82Qmice is
similar to, but less severe than that found in the R6/2 mice. The ﬁrst
detection of phenotypic abnormality is a failure to gain weight with a
signiﬁcant body weight loss over the last 6 weeks of life. In contrast to
the R6 lines of HD mice, seizure activity and hyperkinesis are not
present in the N171-82Q mice. These mice show deﬁcits in the radial
arm water maze test of working and reference memory at 14 weeks
[138]. The commercially available line has a life span range from 130–
180 days. The neuropathological features of the N171-82Q mouse
model are similar to the R6 mice in that they show striatal atrophy,
hyperventricular enlargement, and striatal neuron loss by 16 weeks
[139]. While the original description of these mice did not include
neuronal loss and astrogliosis, these pathological phenomena have
been reported in these mice [139,140]. Huntingtin and ubiquitin-
positive inclusions are found as early as 16 weeks and continue to
increase in number through end-stage disease, particularly in the
pyriform cortex. The phenotype of N171-82Q mice, however, is more
variable than that of R6/2 mice and, as such, a greater number of
N171-82Q mice are needed for preclinical drug trials within the
experimental groups (n= 20). The N171-82Q mice are a useful model
in which to screen drugs using weight loss, performance on the
rotarod test, and survival as outcome measures.
3.2. Murine huntingtin homologue knock-in mice
While this group of HD mice may represent a more precise genetic
model of HD, the knock-in mice models present with a mild and
protracted behavioral and neuropathological phenotype, in contrast to
the fragment models. These mice live a normal life span. An expanded
CAG repeat is inserted into the murine huntingtin homologue and,
therefore, the mutation is genomically correct and under the
endogenous Hdh promoter. The mice can be homozygous or
heterozygous for the mutation. A number of lines have been made
(Table 2). The chimeric HdhQ lines were developed by amutated exon
1 containing either 111 or 92 CAG repeats. These large polyglutamine
repeats cause a CAG repeat instability, predisposing them to
subsequent increases in CAG repeat, resulting in a more fulminant
disease process [113]. Huntingtin-positive puncta are present in
neuronal nuclei by 4.5 months along with an increase in gliosis by
24 months in both of these lines [115]. Mitochondria undergo
compensatory changes in calcium sensitivity in both the Q92 and
Q111 mice [141]. A knock-in Hdh mouse with 72–80 CAG repeats
shows aggressive behavior and neuropil aggregates, but no gliosis or
neuronal loss [114]. These mice develop rotarod impairment.
The HdhQIII knock-in mice have 111 CAG repeats inserted into the
murine HD gene [115]. The mice develop a progressive neuropatho-
logical phenotype with speciﬁcity for striatal neurons, consisting of
nuclear localization of the full-length huntingtin protein in medium
spiny neurons, and subsequent formation of N-terminal inclusions
and insoluble aggregates. The mice eventually develop a late-onset
neurodegeneration and gait deﬁcit in older mice at 24 months of age
[142]. While there were no differences in rotarod and paw-clasping
outcome measures, tunnel walk and stride length revealed a ‘subtle’
Table 2
Knock-in mouse models of HD.
Rodent model CAG repeat Behavioral changes Neuropathology Survival References
Hdh/Q72–80 72–80 Aggressive behavior. No weight
loss. Rotarod impairment.
No neuronal loss or reactive astrogliosis.
Huntingtin aggregates by 28 weeks with nuclear
aggregates by 96 weeks.
Normal life span [102]
HdhQ111 109–111 Gait impairment by 96 weeks. Diffuse huntingtin activity by 6 weeks with nuclear
inclusions by 48 weeks and neuropil aggregates
by 68 weeks. Astrogliosis present by 96 weeks.
Normal life span [103]
CAG140 140 Body weight loss. Initial hyperactivity
at 4 weeks with increased hyperactivity
by 12 weeks. Gait abnormalities by
48 weeks.
Nuclear and neuropil, aggregates are present by
8 months, with diffuse huntingtin activity starting
by 2 months. Neuronal loss.
Normal life span [105,129]
CAG150 150 Body weight loss. Motor performance
deﬁcits on rotarod, gait, and beam balance
by 70–100 weeks.
Striatal huntingtin immunoreactivity at 28 weeks.
Nuclear inclusions at 37 weeks. Reactive astrogliosis at
56 weeks. Loss of striatal neuron perikarya and volume
by 100 weeks in homozygous mice.
Normal life span [104,106]
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were present at 24 months. These neurons were negative for TUNNEL
staining, again suggesting a very ‘subtle’ disease progression as
reported by the authors.
Mice with greater CAG repeats, however, show a less fulminant
phenotype that corresponds to that found in HD patients. A knock-in
mousewith 94 CAG repeats has increased rearing at night at 2 months
of age, decreased activity at 4 and 6 months, but a normal lifespan.
Nuclear microaggregates are present at 4 months and are widely
distributed at 6 months of age in these mice. In mice developed by the
same group with 140 CAG repeats, a very similar pattern of motor
alterations is present [117]. Of interest, disease onset in the 140 CAG
mice occurs much earlier than in the 94 CAGmice, consistent with the
same phenomena in HD patients. The onset of symptoms in HD
patients occurs at a younger age with greater CAG repeat size. In
addition, there is increased motor activity and rearing at 1 month of
age, hypoactivity at 4months of age, and a reduction in stride length at
12 months of age. No signiﬁcant weight loss was observed up to 1 year
of age. Further analysis, however, has shown a much wider range of
motor and behavioral dysfunction [143]. Neuronal loss and reactive
astrogliosis are not present in the 94 CAG, but found in the 140 CAG
mice. The 140 CAG mice show a progressive gliosis, decreases in
dopamine and cAMP-regulated phosphoprotein of 32 kDa (DARPP32)
(a marker of striatal projection neurons) at 12 months, and neuronal
loss at 2 years of age [143]. Huntingtin aggregates are present in both
the 94 CAG and 140 CAG mice, occurring much earlier, at 1 month, in
the 140 CAG knock-in mice. With age, there is a more global presence
of huntingtin aggregates throughout the CNS. We have noted a
derangement in bioenergetic mechanisms, increased oxidative stress,
and factors associated with transcription regulation. The 140 CAG
mice have reduced ATP brain levels, increased 8-hydroxy 2′-
deoxyguanosine, a marker of DNA oxidation, in both brain and
urine, and hypoacetylation of histone activities [144]. We suggest that
the 140 CAGmice maywell be useful in premanifest HD investigations
as well as in therapeutic evaluation.
Another knock-in mouse model with 150 CAG repeats has late-
onset gait abnormalities and develops neuronal intranuclear inclu-
sions predominantly in the striatum [116,118,145]. There is an age-
dependent late-onset behavioral phenotype with signiﬁcant motor
abnormalities at 70 and 100 weeks of age measured by rotarod,
balance beam, and clasping [118]. At 100 weeks the mice exhibit
resting tremor, unsteady movements, and staggering gait. No
signiﬁcant gender differences were observed. There was signiﬁcant
weight loss by 70 and 100 weeks. Gliosis is signiﬁcantly increased by
14 months. Further analysis of this model showed that striatal nuclear
huntingtin and ubiquitin-positive inclusions were initially associated
with the matrix compartment by 27 weeks, the topographic striatal
area ﬁrst thought to be involved in HD patients [106]. In older animals,
nuclear inclusions were distributed evenly in both the striatal patchand matrix compartments by approximately 2 years, nuclear inclu-
sions were present in most brain areas. Dopamine D1 and D2 receptor
binding sites are reduced at 70 and 100 weeks. Striatal neuron loss
was present at 100 weeks, with a 50% loss in striatal perikarya and a
40% reduction in striatal volume. Recent evidence shows NMDA
receptor-mediated excitotoxicity in this mouse line, providing addi-
tional proof that the interaction of huntingtin with NMDA receptors
may be an early event in neuronal death in HD [118]. As with the 140
CAG HD mice, the Hdh (CAG) 150 mice may be useful in identifying
early mechanisms and premanifest biomarkers of disease.
While the knock-in mouse lines do not have a sufﬁcient expression
of disease to use progressive morbidity and survival as an endpoint,
they do have a number of measurable neuropathological and
behavioral phenotypes that can be validated as potential endpoints
in therapeutic studies and may be useful as a secondary model for
conﬁrmation. It is clear that a greater investigation into the
pathophysiological phenomena of these mice is needed.
3.3. Full-length human HD gene transgenic mouse models
Transgenic mice with full-length huntingtin containing 48 or 89
CAG repeats have been described that show behavioral abnormalities
and neuron loss, but have not been available for use in therapeutic
discovery [120]. A yeast artiﬁcial chromosome mouse model of HD
with the entire human huntingtin gene containing 128 CAG repeats
(YAC 128), as well as ﬂanking segments that might involve regulatory
elements, develops motor abnormalities consisting of initial hyper-
activity followed by difﬁculty walking along an elevated rotating rod
from 6 to 12 months, and then hypokinesis [146,147]. There are other
signiﬁcant motor performance declines starting as early as 3 months
that include circling behavior, hindlimb clasping, and gait abnorma-
lities. More recent studies show rotarod and open ﬁeld abnormalities
at 4 and 2 months, respectively [148]. While there is a signiﬁcant body
weight loss in the YAC72 mouse model, there is an increase in body
weight at 2months in the YAC128mouse [148]. Cognitive dysfunction,
as measured by a swim test for procedural learning is similar to the
perseveration observed in HD patients. The motor deﬁcit in the
YAC128 mice correlates with striatal and cortical neuron loss,
providing a structural correlate for the behavioral changes [147].
Neuropathological examination shows decreased striatal and cortical
volume, reduced striatal neuron area and number by 12 months, the
presence of huntingtin immunostaining at 1–2 months, huntingtin
macraggregates starting at 12 months and increasing in number by
18 months in the YAC128 model [148]. The YAC 128 model has been
used extensively to investigate pathogenic mechanisms of HD and
most recently to identify therapeutic strategies. Medium-sized spiny
striatal neurons are more vulnerable to NMDA receptor-mediated
death in the YAC transgenicmousemodel of HD expressing full-length
mutant huntingtin [149]. Both mitochondrial and apoptotic pathways
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has excellent ﬁdelity with human HD. As with the 140 CAG and 150
CAG mice, the length of time for phenotype development may hinder
the use of this model for treatment paradigms unless early biomarkers
of disease can be identiﬁed in the YAC mice.
New transgenic mice, created using a bacterial artiﬁcial chromo-
some (BAC), look promising [151]. These mice have a 240 kb BAC that
contains the entire 170 kb human huntingtin locus. These mice show
progressive motor deﬁcits. They exhibit a signiﬁcant reduction in
rotarod performance at 2 months with worsening behavior through
12 months. The BACHD mice also show a signiﬁcant gain in body
weight, similar to the YAC 128 mice, that plateaus at 12 months. By
12 months there is marked gross brain atrophy and brain weight loss,
with signiﬁcant decreases in both cortical and striatal volume.
Degenerating dark neurons were present in the striatum at 12 months
without signiﬁcant neuronal loss. Huntingtin inclusions were
detected at 12 and 18 months, almost entirely within the cortex and
a few small inclusions within the striatum. Electrophysiological
studies show that spontaneous excitatory transmission is signiﬁcantly
reduced in the BACHD mice, suggesting early abnormalities in cortical
input to striatal neurons. Although these transgenic mice expressing a
full-length mutant huntingtin have not yet been used in a published
therapeutic discovery experiment, there are efforts underway.
A transgenic rat model also exists that expresses 51 human CAG
repeats [152]. Expression of the gene is under an endogenous rat
promoter. The rat is normal at birth and by 24 months has signiﬁcant
body weight loss. There is a progressive poor performance on rotarod
after 2months of age, alongwith cognitive deﬁcits by 12months [153].
Gait abnormalities and head dyskinesias occur starting at 10 months.
The neuropathological sequelae include hyperventricular enlargement
along with huntingtin inclusions present throughout the brain.
3.4. Lentiviral-mediated mutant huntingtin model
A lentiviral delivery of mutant huntingtin has been developed in a
rat model using 44, 66, and 82 repeat fragments [154]. There is an
increased expression of ubiquitinated htt aggregates starting 1 week
after injection with great numbers of inclusions by 4 weeks time.
Striatal neuron degeneration, loss of DARPP-32 staining, and cell death
occur over 6 months. The neurodegeneration is speciﬁc to GABAergic
neurons, with little or no effect on striatal interneurons, consistent
with observations in HD patients.
4. Non-human primate models of HD
Both toxin and genetic primate models of HD exist and play an
important role in extending those ﬁndings observed in HD rodent
models [66,69,99,100,101,155]. While the toxin lesions provide an
experimental model that closely parallels the neuropathological,
neurochemical, and clinical features of HD, a recently developed
transgenic HD rhesus monkey model that expresses expanded
huntingtin polyglutamine shows clinical phenomena that include
dystonia and chorea characteristics of that found in HD patients [155].
While marked expression of huntingtin aggregates were present in
the brains of those monkeys that succumbed to an early death, no
striatal neuron degeneration was present. As HD is a slowly
progressive disorder, it may be years before these monkeys show a
full HD neuropathological phenotype. Clinical follow-up continues
with surviving monkeys. As such, the availability of non-human
primates with HD could be valuable in any ﬁnal analysis evaluating
the most promising therapeutic candidates for HD patients.
5. Biomarkers of Huntington's disease
A major goal of current clinical research in Huntington's disease is
to improve early detection of disease and premanifest detection ofneuronal dysfunction with translation to therapeutic trials. Biomar-
kers are urgently needed for diagnosis, disease progression, and for
potential disease-modifying therapies that are being developed and
evaluated in clinical trials, especially at the preclinical stage. The
development of early premanifest biomarkers is of great importance,
as these may improve the power and cost-effectiveness of drug trials.
As the mechanism of pathogenesis in HD is not yet clear, biomarkers
will be required at all stages of disease and will necessitate multiple
combinations of detection methods. One complementary research
strategy has been to perform parallel correlative biomarker studies in
HD patients and animal models of HD and make comparisons. This
approach takes advantage of advances being made in animal models
to best understand the most effective therapeutic strategies. While
many different approaches have been undertaken to identify
biomarkers, proﬁling objective biomarker measurements of HD has
proven somewhat difﬁcult at the present time. There has been,
however, some advancement in this arena, particularly in R6/2 mice.
It has been shown that biomarkers of protein crosslinking are
signiﬁcantly elevated in both HD patients and in HD mice. Both
transglutaminase and gamma glutamyl lysine activities are signiﬁ-
cantly increased in brain samples in a disease-dependent manner
[156]. There is also evidence that biomarkers of nucleosomal and
bioenergetic dysfunction are present in both HD mice and HD
patients, representing biomarkers as predictors of disease onset and
progression [57]. Lastly, 8-hydroxy-2-deoxyguanosine, a marker of
DNA oxidation, is signiﬁcantly increased in brain and urine from HD
patients and HD mice [144,157,158]. Of great interest are studies using
high-dose creatine in HD patients and in HD mice, showing
parallelism in biomarkers of disease pathogenesis and treatment
efﬁcacy. Creatine treatment signiﬁcantly improves brain creatine
levels and reduces urine levels of 8-hydroxy-2-deoxyguanosine, a
marker of DNA oxidation, in both HD patients and mice [144,157,158].
While it has not yet been conﬁrmed that therapeutic experiments
demonstrating improved phenotype in HD mice are predictive of
beneﬁts in humans, the above evidence demonstrates that mice do
provide value. Correlative biomarker analysis in both mice and man
will provide a more rapid and desirable body of evidence to fully
inform clinical decision-making, and identify what factors contribute
to the equipoise in determining whether preclinical mouse informa-
tion about a therapy makes clinical study warranted in patients. While
the efﬁciency and clear experimental endpoints of the R6/2 mice
remain a major advantage, the fulminant and early expression of
disease in these mice may not allow for premanifest and early
symptomatic identiﬁcation of biomarkers. Full-length knock-in HD
mice, however, may provide the best possible molecular and genetic
comparability to human HD and strengthen the ability to conﬁrm the
detection of biomarkers, especially prior to disease onset, given their
slow disease progression.
6. Methodological considerations for mouse therapeutic trials
Although making the therapeutic leap from genetic models to
humans fulﬁlls one of the promises of molecular medicine, it also
brings risk to human subjects and expends human and ﬁnancial
resources. Thus, how data from experiments using experimental
models are used to inform choices about clinical trials requires
reﬂection and examination. Among the important issues are what
constitutes an informative genetic model, what principals should
be followed in designing experiments using these models, what
body of evidence is desirable to fully inform clinical decision-
making, and what factors contribute to the equipoise in determin-
ing whether preclinical information about a therapy makes human
study warranted.
While toxin models play a role in understanding mechanisms
of excitotoxicity and mitochondrial dysfunction in HD, they fall short
as a reliable model of an autosomal dominant genetic disease
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Toxin models are acute experimental paradigms in contrast to slowly
progressive events that occur over years in HD patients and months
and years in genetic models of HD. As such, this section will focus on
issues related to standardization of experimental therapeutics in
transgenic mouse models of HD and discuss some of the salient issues
related to translation from mice to humans.
Genetic animal models of inherited neurological diseases provide
an opportunity to test potential treatments and explore their promise
for translation to humans experiencing these diseases. Therapeutic
trials conducted in mouse models of HD have identiﬁed a growing
number of potential therapies that are candidates for clinical trials and
have been reviewed in multiple publication venues [28,57]. While it is
very exciting to have these candidates, there has also been increasing
concern about the feasibility and desirability of taking all of the
compounds that may work in mice and testing them in patients with
HD. There is a need to begin to prioritize leads emerging from
transgenic mouse studies, however, it is difﬁcult to compare results
between compounds and laboratories and there are also many
additional factors that can affect translation to humans.
Genetic models encompass a variety of assays inwhich the mutant
gene or some portion of it has been introduced into living organisms
which experience a phenotypic response in some measure indicative
of the human disease. Screening of high-throughput assays using
libraries containing thousands to millions of small molecules can
bring candidate therapies forward based upon obtaining a desired
effect on a biochemical or cellular phenotype, irrespective of knowl-
edge about mechanism of action. However leads arise, proof of
efﬁcacy in mammalian models is considered a requisite before
considering possible testing in humans. For compounds already in
the pharmacopoeia it can be easy to contemplate rapid translation to
clinical trials. For compounds that are not yet pharmaceuticals or
nutriceuticals, efﬁcacy in mammalian models would lead ﬁrst to
standard preclinical pharmacokinetic, toxicity, teratogenicity studies,
and perhaps the development of more promising analogs before
testing can begin in humans. When selecting compounds for study in
preclinical experiments, we have prioritized compounds already in
human use because of the indispensable knowledge base that comes
with them and the existence of pharmaceutical material ready for
human use.
Transgenic mouse models of HD have been extensively used in the
last several years to test potential therapies [28]. While most studies
have concentrated on compounds that have already had human use,
we are also beginning to test leads arriving from screens performed in
cellular and submammalian models. Some of the compounds that we
have demonstrated to be efﬁcacious in transgenic mice have gone on
to clinical testing, often in trials we have also participated in designing
[57]. Through this experience and discussions with many others, we
have developed a perspective about using transgenic mouse experi-
ments to stimulate and guide clinical trials. We have also encountered
a wide range of thoughts in the HD research community, from the
opinion that preclinical studies in mouse models are of limited
signiﬁcance because mice and humans are so different, to suggestions
that there should be rigid criteria for success in the mouse models
before a therapy is considered for human clinical trials. It is quite
complex to consider what constitutes sufﬁcient data from mouse
models to justify translation to humans. The lack of a proven
neuroprotective therapy for HD also effects the equation by keeping
the level of urgency high.
Though there is a need to begin to prioritize leads emerging from
transgenic mouse studies, it may be difﬁcult to compare results
between compounds and laboratories. There are also many additional
factors that can affect the overall desirability of compounds, such as
availability from a manufacturer, expected toxicity, redundancy of
mechanism, and the nature of potential interactions with other
agents. As yet, there have been insufﬁcient fully powered clinical trialsin humans to permit a comparison of therapeutic beneﬁts in the two
species from any given therapy. Thus it has not yet been conﬁrmed
that experiments demonstrating an improved phenotype in trans-
genic mice are predictive of beneﬁts in humans. Similarly, it is
unknown whether the magnitude of beneﬁt in mice predicts the
magnitude of beneﬁt in humans. Nevertheless, results from human
clinical trials will illuminate the value of mouse clinical trials in the
foreseeable future. In the meantime, there are clinical trials being
planned, a growing list of therapies that are effective inmousemodels,
and a need for discussion about how transgenic mouse therapeutic
trial data can best be used.
6.1. Outcome measures
As in human clinical trials, the use of appropriate methodology in
mouse trials determines whether the experimental outcomes are
valid and useful. Many of the same considerations apply both to
human and mouse trials but are not always considered in the latter.
For example, blinding of study personnel about the treatment
condition of the animals they are studying should be standard
practice. A priori power analysis is necessary to establish whether the
study has sufﬁcient numbers of mice for each endpoint. Whereas in
human trials enormous variability is a given; in mouse trials it is
possible to minimize the variability and thereby increase the power to
detect smaller differences in smaller groups. It is important to
understand the genetic, physical, and environmental sources of
variability to take advantage of this.
An estimation of the sample size is a critical ﬁrst step. The numbers
of mice for preclinical studies must be carefully considered and reﬂect
the different outcome measures to be analyzed. Using power analysis,
our experience in survival studies shows that an ‘n’ of 10 in the R6/2
transgenic mice and an ‘n’ of 20 in the N171-82Q transgenic mice in
each experimental group are necessary to have an 80% chance of
detecting a 30% difference between groups. Our experience with
neurohistopathological measures and neurochemical assays has
shown that a standard deviation of 15–20% can be expected. A similar
power analysis suggests that to detect a 30% difference between
groups an ‘n’ of 10 is necessary for each cohort. Others have provided
similar power analyses in detecting differences in huntingtin
accumulation over time in R6/2 mice [159]. A 30% reduction in
huntingtin aggregation is observed at 95% conﬁdence using 10 R6/2
transgenic mice per group. Power calculations also show that the
probability of detecting a deﬁcit in R6/2 mice on the running wheel
and climbing cage was greater than 90% using a group size of 14 mice
[160]. In the full-length human mutant huntingtin bacterial artiﬁcial
chromosome (BAC) transgenic mouse model, power analyses were
performed to estimate the number of mice to rescue disease-relevant
outcomes [151]. Power analysis showing a 30% rescue of rotarod
deﬁcit at 6 months would require 22 BAC mice. In addition power
analysis showed that a sample size of 14 BAC mice was necessary to
detect a 30% rescue of dark neurons, along with 5 and 11 BAC mice,
respectively for a 30% rescue of cortical and striatal volumes. A 15–20%
standard deviation could be expected.
As in human clinical research, it is important to have inclusion and
exclusion criteria, which should be predetermined. For example, there
is good reason to consider excluding ‘runts’ (we routinely exclude
mice weighing less than 8 g at 21 days), mice with injuries, mice in
which CAG repeat length is out of the median range (CAG repeat must
be monitored in the colony), and mice unable to perform some of the
planned evaluations, such as the rotarod. Treatment groups should be
physically and genetically comparable. In particular, there should be a
systematic assignment of mice to experimental groups to prevent
overrepresentation of sibs in any group. For example, it can be
predetermined that nomore than one or twomice from any litter be in
a given experimental group. Mice should be evenly distributed into
cohorts by body weight. The environment in which these mice are
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enrichment slows disease progression in HD mice and may be
considered a therapeutic treatment in and of itself [161]. Another
important consideration is the onset and duration of treatment in
mouse trials. Initiation of treatment at weaning, as has been most
common, is analogous to treating presymptomatic humans. Initiation
of treatment once a motor or other clinical phenotype is evident
would be analogous to most human trials for HD, the latter of which
have generally used early symptomatic subjects.
6.1.1. Primary measures
There are many potential outcome measures that can be used in
mouse therapeutic trials. These bear close examination because they
can differ enormously in relevance with some clearly being much
more informative and speciﬁc than others. For clarity, in neurode-
generative disease research we are especially concerned with
achieving neuroprotection, which at its most basic level is the
preservation of neuronal processes, somata, and function. Measures
that assess these directly (brain weight, gross atrophy, cellular
atrophy, neuronal counts, gliosis, volumetric imaging) should be
considered the primary outcome measures. While it may also be
possible to model the treatment of symptoms in genetic models and it
may also happen that improving symptoms corresponds to neuro-
protection, assessments of symptoms should be considered secondary
outcome measures. The reason for this is that symptoms can be
modiﬁed without affecting neurodegeneration, for example by
modifying motivation, level of consciousness, energy, etc. This
distinction is important to keep in mind when considering how
informative the results of a mouse therapeutic trial might be for
considering translation to humans. A treatment cannot be considered
to be neuroprotective in mice in the absence of neuropathological
evidence that brain atrophy, cellular atrophy, or neuronal loss has
been prevented. The quality of neuropathology in mouse therapeutic
trials is thus of foremost importance. It should also be mentioned that
other neuropathological measures, such as protein aggregate load or
the expression of molecules of interest, are only meaningful if brain
atrophy, cellular atrophy, or neuronal loss are measured to provide a
context for interpreting them.
In our labs, cohorts of treated and untreated wild-type and mutant
littermate mice, are euthanized at early, moderate, and late stages of
their phenotypes for neuropathological analysis. Standardization of
tissue processing is critical to the analysis. As an example, cut tissue
sections mounted from water will expand and those mounted from
phosphate buffer will contract, resulting in entirely different brain
measures. Brain specimens are identiﬁed by the originally assigned
code so that the subsequent studies are performed blind to the
investigator as to the genetic identity and treatment of the mice.
Quantitative methods are essential as observation alone can only
detect large differences and semi-quantitative methods are prone to
many types of errors. We use stereology to obtain various brain and
cellular volumes and counts and also to quantify other pathological
features, such as huntingtin aggregates.
6.1.2. Secondary measures
Secondary outcome measures include survival, body weight,
performance on motor and cognitive tasks, and laboratory studies
examining toxicity or putative mechanisms of action. These should
be completed at the same time of day because of diurnal and
circadian rhythms. Mouse survival, or a surrogate for mouse survival,
which are usually criteria for advanced morbidity that agrees with an
institution's animal care policies and triggers euthanasia, is an
especially useful secondary outcome measure. Besides generally
correlating well with neuropathology, it provides a relevant measure
of the magnitude of beneﬁt that is both understandable and enables
ready comparison with other therapies. A dose versus survival study
is recommended, using at least three doses demonstrating nosigniﬁcant efﬁcacy, signiﬁcant efﬁcacy, and signiﬁcantly greater
morbidity and/or mortality in mutant mice. It is important to
observe mice in any treatment paradigm twice daily throughout the
experiment for any signs of morbidity and mortality. Strict criteria
are necessary to determine when mice should be euthanized. While
this may vary between institutions, our own criteria for euthaniza-
tion is the point in time when the mice are unable to initiate
movement and right themselves after being placed upon their side
and gently prodded for 30 s. Two independent observers conﬁrm
these criteria.
While body weight has often showed early and signiﬁcant
improvements in some mouse therapeutic trials, little effect has also
been observed in other trials despite dramatic improvement in
survival. Our practice is to measure body weight weekly, on the
same day, usually from the time of weaning. Diurnal feeding habits
necessitate that weights be taken at the same time, morning or
afternoon. As mice progress towards the latter stages of disease, we
usually increase the frequency of weighing to twice weekly.
A variety of motor tasks have been used in mice to assess the
clinical phenotype. These include measuring activity and grooming,
the length of time a mouse can balance on a rotating rod, grip
strength measurement, and gait. Preserved motor performance
correlates with improved survival and neuroprotective outcomes,
though compounds administered to the CNS can also have
pharmacological affects that independently modify motor perfor-
mance. The rotarod test, in which mice are required to walk along
an elevated rotating rod, is generally accepted as the most sensitive
and encompassing and is widely used. This equipment is commer-
cially available and its use has been standardized within most
laboratories and can be compared across experimental studies. In
the fragment models, we perform testing twice weekly. There are a
number of variations of rotational speed and whether the rod is at a
constant speed or accelerating which investigators have applied. The
length of time that the mice remain on the rotating rod is used as
the measure of competency on this task. Mice are tested until they
are unable to perform. On any given day, mice may fail or refuse to
perform this task. If this occurs early on in the time course of
disease phenotype, additional repeated trials the next day may be
useful to ensure that performance failure is a reﬂection of disease. In
the absence of a rotarod apparatus, the onset of forelimb and
hindlimb clasping, a measure of neurological abnormality in HD
mice, can be assessed daily until identiﬁed and conﬁrmed by a
second investigator.
Declining cognition occurs early in HD and the mouse models are
expected to develop cognitive deﬁcits as well. However, few cognitive
assessments have been validated in the mouse models currently in
use. In the fragment models, it is difﬁcult to complete training before
the phenotype has already compromised performance. Nevertheless
water maze, habituation to acoustic startle, and prepulse inhibition
have been used by a number of investigators and efforts to develop
further cognitive tests, such as serial reaction time and other implicit
memory tasks are ongoing [162,163]. Cognitive endpoints may prove
especially valuable in the full-length models in which motor
symptoms are slow to develop.
Open Field Testing, which assesses general activity, is a complex
measure that may be most useful in the full-length models that
progress more slowly. Commercially available units to detect move-
ment can analyze and quantify multiple motor behaviors. In our
laboratory, testing is usually performed during the dark phase of the
diurnal cycle when mice are most active. Measurements can be made
during the ﬁrst 15–30 min interval after placement in a novel open
ﬁeld. Horizontal and vertical motions can be counted and locomotor
activity, rearing, circling, and grooming assessed. The open ﬁeld box
must be cleaned between mice to prevent behavioral effects from the
odors of previous occupants. Testing is performed every other week in
the R6/2 and N171-82Q models and once a month in the full-length
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the measured behavior. There can be some speciﬁc differences in the
patterns of behaviors observed. For example, some HD mice seem to
continually repeat an abortive grooming process.
A behavioral observation system, SHIRPA, is a three stage, semi-
quantitative protocol designed to characterize phenotype changes in
mice. In therapeutic trials, behavioral and functional changes are
scored by an observer blinded to treatment [164]. A composite score is
calculated following the assessment. A modiﬁed SHIRPA has been
developed for longitudinal use in mice with neurological disease
[165]. The utility of such a behavioral protocol is in its standardization
and may be a useful cross measure for all laboratories performing
therapeutic drug trials in mice with neurological disease. The scoring,
however, requires detailed scrutiny of some behaviors and function in
HD mice that are subject to interpretation, such as limb clasping and
physical appearance. For this reason, it is also important to maintain
observer consistency throughout a study.
6.1.3. Pharmacokinetic studies
Several types of laboratory studies contribute crucial information
that can greatly enrich the preclinical information about a com-
pound. Pharmacokinetic analysis of the study compound, its
metabolites, or of molecules expected to be affected by the
treatment, help to insure that the compound reaches the brain and
performs as expected. Pharmacokinetic studies are useful in
combination drug trials to examine the effects on bioavailability of
one compound in relation to the other compound. Additionally,
understanding effective doses in mice, along with blood and brain
levels, can set the stage for asking whether such doses and levels can
be achieved in humans. In our experience, 0.5–1.0 ml of blood is
required to produce sufﬁcient serum for testing levels of agents and
it is collected by cardiac puncture, requiring euthanization. HPLC
with electrochemical detection along with spectrometric analysis are
the methods of choice [156,166]. Because pharmacokinetic studies
provide critical information regarding optimal dosing, our current
approach has been to perform maximum-tolerated-dose studies to
determine the LD50 dose starting at a minimum tolerated dose
based upon previously available ADMET data and increase the dose
one fold b.i.d. each administration over the course of 14 days or until
LD50 is reached. In addition, we employ a pharmacokinetic model to
identify a series of concentration-time data points in blood, urine,
and brain. The bioequivalence is evaluated by comparison of
variables such as peak concentration, time of peak concentration,
elimination half-life, and area under the concentration curve in each
tissue sample. These experimental studies are completed in both
wild-type and mutant mice prior to a drug trial in mice and allow us
to determine the optimal pharmacokinetic parameters for dosing the
mice. In addition to pharmacokinetic studies, it can be very helpful
to perform pharmacodynamic studies aimed at determining whether
a compound's expected mechanism of action is actually working.
Both brain and peripheral body tissue samples are used in the
analyses. This can be important as many compounds have multiple
potential mechanisms of action. We currently assess nucleosomal
(histone acetylation and methylation) and bioenergetic (ATP/ADP/
AMP, creatine, phosphocreatine, and coenzyme Q10 and Q9 levels)
dysfunction, along with 8-hydroxy-2-deoxyguanosine concentra-
tions, a marker of DNA oxidation. Each of these biomarkers of
disease is signiﬁcantly altered in both central and peripheral tissue
samples [57]. It is additionally important to determine whether any
of the treatments might work by suppressing expression of the
huntingtin transgene, since this might help the mice but not humans
in the absence of identical regulation. This is especially important in
mouse lines in which expression is regulated by exogenous
promoters and for drugs that affect aggregate formation and gene
transcription [167]. Transgene expression can be analyzed using
Western and Northern assays, as well as real time-PCR methods.6.1.4. Therapeutic strategies
Many potential therapies have now been tested in genetic models
of HD and some have been demonstrated to be neuroprotective in
HD transgenic mice. Efﬁcacy in mouse trials has provided the
rationale for a number of clinical trials that have already occurred or
are planned. These include coenzyme Q10, creatine, remacemide,
riluzole, minocycline, ethyl-epa, phenylbutyrate, and cysteamine
[57]. Most of these have been early phase clinical trials, so the
predictive value of the mouse therapeutic trials are not yet known.
However, because these are actually very good models at many
levels of analysis, it would be surprising if some compounds
beneﬁting the mouse models did not prove to beneﬁt humans
with HD. Since clinical trials may be expensive, effortful, and years in
length depending on the type, there is growing discussion within
neurodegenerative disorder clinical trials organizations, such as the
Huntington Study Group and sponsors, about how much preclinical
information is enough and how to prioritize among many efﬁcacious
compounds. Of course the bar should be higher for later phase trials
and higher when the interventions have greater potential for risks to
human subjects.
The impact therapeutic trials in genetic models can have on
selecting compounds for clinical trials in humans depends on many
factors relating to the quality and breadth of the preclinical data, as
well as on the potential risks and beneﬁts to performing the clinical
trials. In this review, we have discussed the many factors that affect
the quality of an individual mouse therapeutic trial. Of course, the
highest quality studies and those with the most robust neuroprotec-
tion should have the greatest impact. Neuropathological evidence of
neuroprotection remains the most important ﬁnding with all other
outcomes potentially providing additional support. Since the numbers
of compounds demonstrating some efﬁcacy continues to grow, an
issue of growing importance is the question of how to compare their
efﬁcacy to better prioritize them. Since procedures differ between
labs, since the models have many differences, and since even the same
mouse line can have different phenotypes in different labs because of
genetic drift, background strain differences, and/or the presence of
microbes within individual vivaria, it is difﬁcult to compare the
magnitude of one treatment's effect with another's. We would
propose that laboratories performing therapeutic trials in mouse
models use positive control compounds to help place their results in
context. For example, several labs have replicated beneﬁts with
cystamine, so including a cystamine treatment cohort in trials of more
novel therapeutics could help calibrate results [57].
As in human clinical trials, the use of appropriate methodology in
mouse trials determines whether the experimental outcomes are
valid and useful. Many of the same considerations apply to both
human and mouse trials but are not always considered in the latter.
Based upon our experience, positive outcomes in mice are critical
indicators in determining whether compound efﬁcacy provides
sufﬁcient information to fully inform human clinical-trial decision-
making. While there are many different outcomes that could be used
in characterizing drug efﬁcacy, the following minimum guideline
criteria are essential to strengthen the evidence for drug translation
to patients.
1. Blinding of study personnel about the treatment condition of the
animals they are studying should be standard practice.
2. Power analyses are necessary to establish whether the study has
sufﬁcient numbers of mice for each endpoint.
3. Use of both fragment and full-length HD mouse models in
preclinical drug trials once the potential of a compound has been
established. Our current standard measure has been the R6/2
with conﬁrmation in the 140 CAG HD mice.
4. As in human clinical research, it is important to have inclusion and
exclusion criteria in order to exclude bias (e.g. CAG repeat size,
body weight, parental inheritance). Treatment groups should be
517R.J. Ferrante / Biochimica et Biophysica Acta 1792 (2009) 506–520genetically comparable to prevent overrepresentation of sibs into
any experimental cohort.
5. A dose versus survival study is recommended, using at least three
doses, to decide whether therapeutic beneﬁts stabilize (saturate) or
decline past the optimum dose determined by pharmacokinetic
studies.
6. Conﬁrmation of experimental ﬁndings in at least one independent
laboratory.
7. Rotarod Test: 20% and 15% improvement in R6/2 and 140 CAG
mice, respectively.
8. Open Field Test: 20% and 15% improvement in R6/2 and 140 CAG
mice, respectively.
9. Survival extension of at least 15% in R6/2 mice. Survival is deﬁned
as meeting the criteria for euthanasia in accordance with the
institution IACUC guidelines.
10. Neuropathological measures that include a 20% reduction in gross
brain and ventricular measurements, a 25% reduction in hunting-
tin aggregate load, and a 30% reduction in neuronal cell atrophy
and/or neuronal loss using unbiased stereology.
11. At least one pharmacodynamic or biochemical measure that
correlates globally with phenotypic progression and neuroprotec-
tion in mice and humans. We use 8-hydroxy-2-deoxyguanosine
concentrations, as they are elevated in urine and brain in both HD
patients and HD mice. This measure can be developed to the
speciﬁc compound in use.
There is a growing body of evidence suggesting that the
phenotypes from mouse models of neurological diseases closely
correlate with human diseases and may validate known CNS drug
targets in a therapeutically relevant manner. The strengths of the HD
mouse models are in their utility to provide parallel pathophysiolo-
gical targets that are present in HD patients, in their potential as
sensitive predictors for therapeutic intervention, and their promise in
the development of novel drug agents. While drug trials in mice
conﬁrm therapeutic direction, the challenge is in determining what
dose might be of value in patients since the pharmacokinetics of mice
and man is dissimilar.
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